Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Researchers uncover critical role for two proteins in chromatin structure

A team of researchers at the IRCM led by François Robert, PhD, uncovered a critical role for two proteins in chromatin structure. Their breakthrough, recently published in the scientific journal Molecular Cell, helps explain how DNA is organized in our cells. This discovery could lead to a better understanding of what causes certain types of cancer, such as lymphoma.

30 May 2015

FVCG portfolio companies selected to present research at Bio International 2015

Actinobac Biomed, NovoPedics, Inc. and MentiNova, Inc., three biotech start-up companies originally funded with investments from Foundation Venture Capital Group (FVCG), have been selected to present their research at Bio International 2015 as part of the Start-Up Stadium and Company Presentation forums offered at the Conference, announced FVCG President James M. Golubieski.

30 May 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Data to be presented at the 51st Annual Meeting of the American Society of Clinical Oncology suggest that the investigational immunotherapy MPDL3280A may double the likelihood of overall survival in the study period (HR=0.47), compared with docetaxel chemotherapy, in individuals with non-small cell lung cancer (NSCLC) who expressed the highest levels of PD-L1 (a receptor present on cancer cells).

30 May 2015

Skin Cancer Awareness Recommended For HCT Recipients

Patients who undergo haematopoietic cell transplantation should be educated on the risk of skin cancer and the need for regular self-examination, US researchers say.

29 May 2015

Hodgkin's lymphoma treatment can cause late sequelae

Hodgkin's lymphoma--cancer of the lymph nodes--arises in more than 150 children and adolescents in Germany each year. Nine out of ten patients survive the disease, thanks to the highly effective treatments that are now available. Depending on the type of treatment given, however, there may be late sequelae, as discussed by Wolfgang Dörffel and colleagues in an original article in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2015; 112: 320-7).

29 May 2015

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries.

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Scorpion venom could kill cancer cells

When the toxin invades channels in the cells with this disease produces cellular damage until killing them.

27 May 2015

Tiny drug-delivery system can help identify brain tumor types through 'virtual biopsies'

Biomedical researchers at Cedars-Sinai have invented a tiny drug-delivery system that can identify cancer cell types in the brain through "virtual biopsies" and then attack the molecular structure of the disease.

27 May 2015

GFG's 'A Bite for the Fight' campaign raises over $1 million for The Leukemia & Lymphoma Society

Global Franchise Group, LLC, the strategic brand management company and franchisor behind Great American Cookies, Pretzelmaker, Marble Slab Creamery, MaggieMoo's Ice Cream & Treatery, and Hot Dog on a Stick has raised more than $1 million for The Leukemia & Lymphoma Society through its "A Bite for the Fight" campaign.

26 May 2015

TGen and Baylor partnership set to increase treatment options for cancer patients

The Translational Genomics Research Institute (TGen) and Baylor Research Institute (BRI) at Dallas today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.

22 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found.

15 May 2015

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation.

15 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

New study finds link between father's age at birth and child's risk of blood cancer as an adult

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, which appears in the American Journal of Epidemiology, found no association between having an older mother and these cancers.

12 May 2015

Research findings could lead to new targeted treatments for aggressive subtype of lymphoma

An international team of researchers, including Lukas Kenner from the Clinical Department of Pathology at MedUni Vienna, has discovered a specific combination of mutations and new gene fusions, which are heavily implicated in tumour growth in patients with a particularly aggressive subtype of lymphoma (ALCL).

11 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

Lymphoma News and Research

Further Reading

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Researchers uncover critical role for two proteins in chromatin structure

FVCG portfolio companies selected to present research at Bio International 2015

Roche’s immunotherapy MPDL3280A better than chemotherapy in improving overall survival in NSCLC patients

Skin Cancer Awareness Recommended For HCT Recipients

Hodgkin's lymphoma treatment can cause late sequelae

Study: New cases of cancer rising globally, but death rates falling in many countries

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Scorpion venom could kill cancer cells

Tiny drug-delivery system can help identify brain tumor types through 'virtual biopsies'

GFG's 'A Bite for the Fight' campaign raises over $1 million for The Leukemia & Lymphoma Society

TGen and Baylor partnership set to increase treatment options for cancer patients

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Soligenix, Emergent BioSolutions sign development agreement

New study finds link between father's age at birth and child's risk of blood cancer as an adult

Research findings could lead to new targeted treatments for aggressive subtype of lymphoma

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News